Piper Sandler analyst David Westenberg raised the firm’s price target on Natera to $80 from $70 and keeps an Overweight rating on the shares after the company received a Centers for Medicare and Medicaid Services decision stating the agency will cover Signatera for most Medicare breast cancer patients. The analyst thinks this could add $30M in revenue to Signatera and help offset the reproductive health headwinds into the print. Piper estimates more than 80% of Signatera volumes are in a covered indication, which should help drive the selling price up quickly in 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- New paper highlights clinical utility of Natera’s Renasight in kidney disease
- Raymond James Sees ‘Multiple Expansion’ to Drive Stock Market Returns — Here Are 2 Stocks to Play That Bullish Sentiment
- Natera announces new data on MRD test to be presented at ASCO GI 2023
- Natera upgraded to Outperform from Market Perform at Raymond James
- Natera study data adds evidence for Signatera, says SVB Securities